Symbols / BIVI
BIVI Chart
About
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 9.43M |
| Enterprise Value | -10.80M | Income | -17.48M | Sales | — |
| Book/sh | 2.56 | Cash/sh | 2.72 | Dividend Yield | — |
| Payout | 0.00% | Employees | 13 | IPO | — |
| P/E | — | Forward P/E | -0.28 | PEG | — |
| P/S | — | P/B | 0.49 | P/C | — |
| EV/EBITDA | 0.60 | EV/Sales | — | Quick Ratio | 6.90 |
| Current Ratio | 7.25 | Debt/Eq | 1.64 | LT Debt/Eq | — |
| EPS (ttm) | -3.28 | EPS next Y | -4.41 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-11 | ROA | -47.20% |
| ROE | -80.74% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 7.54M |
| Shs Float | 7.50M | Short Float | 2.60% | Short Ratio | 1.66 |
| Short Interest | — | 52W High | 15.10 | 52W Low | 1.06 |
| Beta | 0.56 | Avg Volume | 104.33K | Volume | 54.30K |
| Target Price | — | Recom | None | Prev Close | $1.25 |
| Price | $1.25 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.25
Latest analyst target
3. DCF / Fair value
$-19.76
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.25
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-07-01 | init | ThinkEquity | — → Buy | $3 |
| 2023-11-30 | main | Oppenheimer | Outperform → Outperform | $5 |
| 2023-08-22 | reit | Cantor Fitzgerald | Overweight → Overweight | $11 |
| 2023-07-18 | reit | Cantor Fitzgerald | Overweight → Overweight | $11 |
| 2023-05-17 | reit | Cantor Fitzgerald | Overweight → Overweight | $11 |
| 2023-05-17 | reit | Oppenheimer | Outperform → Outperform | $12 |
| 2023-02-14 | reit | Oppenheimer | — → Outperform | $12 |
| 2022-09-28 | main | EF Hutton | — → Buy | $8 |
| 2022-07-22 | init | Cantor Fitzgerald | — → Overweight | $7 |
| 2022-03-17 | main | EF Hutton | — → Buy | $14 |
| 2022-03-15 | init | Oppenheimer | — → Outperform | $9 |
| 2021-11-30 | main | B. Riley Securities | — → Buy | $27 |
| 2021-01-15 | init | B. Riley FBR | — → Buy | $47 |
- Alzheimer’s and Long COVID drug update: BioVie plans March 4 webcast - Stock Titan Mon, 23 Feb 2026 13
- What Makes BioVie (BIVI) a New Buy Stock - Yahoo Finance hu, 11 Dec 2025 08
- Why Is BioVie Stock (BIVI) Down 50% Today? - TipRanks Fri, 08 Aug 2025 07
- Bull Bear: Is BIVI stock technically oversold - Gap Up & Verified Swing Trading Watchlist - baoquankhu1.vn Sun, 22 Feb 2026 02
- symbol__ Stock Quote Price and Forecast - CNN hu, 16 Nov 2023 01
- Clinical-Stage Biotech BioVie Secures $12M Financing: Key Details of Stock and Warrant Offering Revealed - Stock Titan hu, 07 Aug 2025 07
- Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9 - GlobeNewswire Wed, 19 Nov 2025 08
- Biovie stock plunges after pricing $12 million public offering - Investing.com Fri, 08 Aug 2025 07
- Nexalin Technology and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Columbia Daily Tribune Fri, 17 Oct 2025 07
- Option Therapeutics Files For IPO Of 2.3 Million Shares Of Common Stock - SEC Filing - TradingView Mon, 26 Jan 2026 08
- INVESTOR ALERT: Potential Recovery for BioVie Inc. (BIVI) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire Sat, 10 May 2025 02
- BioVie stock dips on pricing $12M securities offering - MSN Fri, 08 Aug 2025 07
- BioVie Inc. Announces Closing of $12 Million Public Offering - Yahoo Finance Mon, 11 Aug 2025 07
- Biovie stock plunges after pricing $12 million public offering By Investing.com - Investing.com UK Fri, 08 Aug 2025 07
- BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire hu, 09 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 5000 | 14550 | — | Purchase at price 2.91 per share. | DO CUONG VIET | Chief Executive Officer | — | 2025-08-07 00:00:00 | I |
| 1 | 32700 | — | — | Stock Award(Grant) at price 0.00 per share. | ROGICH SIGMUND A | Director | — | 2024-11-20 00:00:00 | D |
| 2 | 34200 | — | — | Stock Award(Grant) at price 0.00 per share. | BERMAN RICHARD JAY | Director | — | 2024-11-20 00:00:00 | D |
| 3 | 168000 | — | — | Stock Award(Grant) at price 0.00 per share. | DO CUONG VIET | Chief Executive Officer | — | 2024-06-24 00:00:00 | I |
| 4 | 73000 | — | — | Stock Award(Grant) at price 0.00 per share. | KIM JOANNE WENDY | Chief Financial Officer | — | 2024-06-24 00:00:00 | D |
| 5 | 116000 | — | — | Stock Award(Grant) at price 0.00 per share. | PALUMBO JOSEPH M | Officer | — | 2024-06-24 00:00:00 | D |
| 6 | 10000 | 10650 | — | Purchase at price 1.06 per share. | DO CUONG VIET | Chief Executive Officer | — | 2024-03-04 00:00:00 | I |
Financials
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -16.98M | -30.81M | -44.29M | -26.98M |
| TotalUnusualItems | 3.77K | 1.82M | -1.44M | 3.29M |
| TotalUnusualItemsExcludingGoodwill | 3.77K | 1.82M | -1.44M | 3.29M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -17.54M | -32.12M | -50.26M | -26.08M |
| ReconciledDepreciation | 229.38K | 229.38K | 229.38K | 229.38K |
| EBITDA | -16.98M | -29.00M | -45.73M | -23.69M |
| EBIT | -17.21M | -29.23M | -45.96M | -23.92M |
| NetInterestIncome | 520.31K | -1.76M | -3.74M | -2.12M |
| InterestExpense | 332.72K | 2.89M | 4.30M | 2.16M |
| InterestIncome | 853.03K | 1.14M | 562.26K | 44.08K |
| NormalizedIncome | -17.55M | -33.94M | -48.82M | -29.37M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -17.54M | -32.12M | -50.26M | -26.08M |
| TotalExpenses | 18.07M | 32.18M | 45.08M | 27.25M |
| TotalOperatingIncomeAsReported | -18.07M | -32.18M | -45.08M | -27.25M |
| DilutedAverageShares | 1.48M | 451.85K | 324.83K | 246.62K |
| BasicAverageShares | 1.48M | 451.85K | 324.83K | 246.62K |
| DilutedEPS | -12.12 | -73.05 | -154.70 | -106.00 |
| BasicEPS | -12.12 | -73.05 | -154.70 | -106.00 |
| DilutedNIAvailtoComStockholders | -17.91M | -33.01M | -50.26M | -26.08M |
| NetIncomeCommonStockholders | -17.91M | -33.01M | -50.26M | -26.08M |
| OtherunderPreferredStockDividend | 369.46K | 886.42K | 0.00 | 0.00 |
| NetIncome | -17.54M | -32.12M | -50.26M | -26.08M |
| NetIncomeIncludingNoncontrollingInterests | -17.54M | -32.12M | -50.26M | -26.08M |
| NetIncomeContinuousOperations | -17.54M | -32.12M | -50.26M | -26.08M |
| PretaxIncome | -17.54M | -32.12M | -50.26M | -26.08M |
| OtherIncomeExpense | 3.77K | 1.82M | -1.44M | 3.29M |
| SpecialIncomeCharges | 0.00 | -130.58M | ||
| OtherSpecialCharges | 130.58M | |||
| GainOnSaleOfSecurity | 3.77K | 1.82M | -1.44M | 3.29M |
| NetNonOperatingInterestIncomeExpense | 520.31K | -1.76M | -3.74M | -2.12M |
| InterestExpenseNonOperating | 332.72K | 2.89M | 4.30M | 2.16M |
| InterestIncomeNonOperating | 853.03K | 1.14M | 562.26K | 44.08K |
| OperatingIncome | -18.07M | -32.18M | -45.08M | -27.25M |
| OperatingExpense | 18.07M | 32.18M | 45.08M | 27.25M |
| DepreciationAmortizationDepletionIncomeStatement | 229.38K | 229.38K | 229.38K | 229.38K |
| DepreciationAndAmortizationInIncomeStatement | 229.38K | 229.38K | 229.38K | 229.38K |
| Amortization | 229.38K | 229.38K | 229.38K | 229.38K |
| AmortizationOfIntangiblesIncomeStatement | 229.38K | 229.38K | 229.38K | 229.38K |
| ResearchAndDevelopment | 9.27M | 23.10M | 33.30M | 17.26M |
| SellingGeneralAndAdministration | 8.57M | 8.85M | 11.55M | 9.77M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | |
|---|---|---|---|---|
| TreasurySharesNumber | 2.84K | 2.63K | 228.00 | |
| OrdinarySharesNumber | 1.91M | 619.01K | 364.29K | 249.84K |
| ShareIssued | 1.92M | 621.64K | 364.52K | 249.84K |
| TotalDebt | 349.89K | 6.11M | 14.42M | 12.26M |
| TangibleBookValue | 18.49M | 14.75M | 14.36M | 2.46M |
| InvestedCapital | 19.01M | 21.21M | 29.67M | 15.81M |
| WorkingCapital | 18.42M | 14.70M | 19.55M | 14.61M |
| NetTangibleAssets | 18.49M | 14.75M | 14.36M | 2.46M |
| CapitalLeaseObligations | 349.89K | 410.24K | 87.41K | 126.30K |
| CommonStockEquity | 19.01M | 15.51M | 15.34M | 3.67M |
| TotalCapitalization | 19.01M | 15.51M | 20.57M | 15.81M |
| TotalEquityGrossMinorityInterest | 19.01M | 15.51M | 15.34M | 3.67M |
| StockholdersEquity | 19.01M | 15.51M | 15.34M | 3.67M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 176.59K | ||
| OtherEquityAdjustments | 176.59K | |||
| TreasuryStock | 29.00 | 27.00 | 2.00 | 0.00 |
| RetainedEarnings | -352.14M | -334.23M | -301.23M | -250.97M |
| AdditionalPaidInCapital | 371.15M | 349.73M | 316.39M | 254.64M |
| CapitalStock | 7.48K | 6.23K | 3.64K | 2.50K |
| CommonStock | 7.48K | 6.23K | 3.64K | 2.50K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.55M | 9.70M | 19.76M | 16.44M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 275.43K | 349.89K | 5.27M | 12.27M |
| OtherNonCurrentLiabilities | 48.38K | |||
| LongTermDebtAndCapitalLeaseObligation | 275.43K | 349.89K | 5.27M | 12.23M |
| LongTermCapitalLeaseObligation | 275.43K | 349.89K | 42.51K | 87.41K |
| LongTermDebt | 5.23M | 12.14M | ||
| CurrentLiabilities | 2.27M | 9.35M | 14.49M | 4.17M |
| OtherCurrentLiabilities | 3.77K | 1.87M | 1.69M | |
| CurrentDebtAndCapitalLeaseObligation | 74.46K | 5.76M | 9.15M | 38.88K |
| CurrentCapitalLeaseObligation | 74.46K | 60.34K | 44.91K | 38.88K |
| CurrentDebt | 5.70M | 9.11M | ||
| OtherCurrentBorrowings | 5.70M | 9.11M | ||
| PayablesAndAccruedExpenses | 2.20M | 3.59M | 3.48M | 2.44M |
| TotalAssets | 21.56M | 25.21M | 35.10M | 20.11M |
| TotalNonCurrentAssets | 863.71K | 1.16M | 1.06M | 1.33M |
| OtherNonCurrentAssets | 4.56K | |||
| GoodwillAndOtherIntangibleAssets | 524.05K | 753.43K | 982.81K | 1.21M |
| OtherIntangibleAssets | 178.34K | 407.72K | 637.10K | 866.47K |
| Goodwill | 345.71K | 345.71K | 345.71K | 345.71K |
| NetPPE | 339.65K | 406.73K | 80.79K | 118.25K |
| GrossPPE | 339.65K | 406.73K | 80.79K | 118.25K |
| OtherProperties | 80.79K | 118.25K | ||
| BuildingsAndImprovements | 339.65K | 406.73K | 80.79K | 118.25K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 20.70M | 24.05M | 34.04M | 18.78M |
| OtherCurrentAssets | 1.05M | 204.39K | 102.53K | 137.88K |
| PrepaidAssets | 137.88K | 93.49K | ||
| Receivables | 2.10M | 0.00 | ||
| OtherReceivables | 2.10M | |||
| CashCashEquivalentsAndShortTermInvestments | 17.54M | 23.84M | 33.94M | 18.64M |
| OtherShortTermInvestments | 0.00 | 14.48M | 0.00 | |
| CashAndCashEquivalents | 17.54M | 23.84M | 19.46M | 18.64M |
| CashEquivalents | 13.57M | 11.08M | 13.16M | |
| CashFinancial | 3.98M | 12.76M | 6.30M | 18.64M |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -19.03M | -27.95M | -40.25M | -18.99M |
| RepaymentOfDebt | -5.85M | 0.00 | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | 14.61M | 436.00K | |
| IssuanceOfCapitalStock | 15.67M | 27.80M | 55.37M | 18.51M |
| InterestPaidSupplementalData | 183.93K | 1.53M | 2.11M | 964.24K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | ||
| EndCashPosition | 17.54M | 23.84M | 19.46M | 18.64M |
| BeginningCashPosition | 23.84M | 19.46M | 18.64M | 4.51M |
| ChangesInCash | -6.30M | 4.38M | 819.17K | 14.13M |
| FinancingCashFlow | 12.73M | 17.80M | 55.37M | 33.12M |
| CashFlowFromContinuingFinancingActivities | 12.73M | 17.80M | 55.37M | 33.12M |
| ProceedsFromStockOptionExercised | 2.90M | -10.00M | 2.24K | 0.00 |
| NetCommonStockIssuance | 15.67M | 27.80M | 55.37M | 18.51M |
| CommonStockIssuance | 15.67M | 27.80M | 55.37M | 18.51M |
| NetIssuancePaymentsOfDebt | -5.85M | 0.00 | 0.00 | 14.61M |
| NetShortTermDebtIssuance | -5.85M | 0.00 | 14.61M | 0.00 |
| ShortTermDebtPayments | -5.85M | 0.00 | -1.82M | |
| ShortTermDebtIssuance | 14.61M | 0.00 | ||
| NetLongTermDebtIssuance | -10.00M | 0.00 | 14.61M | -1.39M |
| LongTermDebtPayments | -10.00M | 0.00 | 0.00 | -1.82M |
| LongTermDebtIssuance | 0.00 | 14.61M | 436.00K | |
| InvestingCashFlow | 0.00 | 14.53M | -14.30M | 0.00 |
| CashFlowFromContinuingInvestingActivities | 0.00 | 14.53M | -14.30M | 0.00 |
| NetInvestmentPurchaseAndSale | 0.00 | 14.53M | -14.30M | 0.00 |
| SaleOfInvestment | 0.00 | 14.53M | ||
| PurchaseOfInvestment | -14.30M | 0.00 | ||
| OperatingCashFlow | -19.03M | -27.95M | -40.25M | -18.99M |
| CashFlowFromContinuingOperatingActivities | -19.03M | -27.95M | -40.25M | -18.99M |
| ChangeInWorkingCapital | -4.40M | -86.84K | -270.44K | 2.75M |
| ChangeInOtherCurrentLiabilities | -60.34K | -95.63K | -1.34M | 1.35M |
| ChangeInOtherCurrentAssets | -48.95K | 282.30K | ||
| ChangeInPayablesAndAccruedExpense | -1.39M | 110.65K | 1.03M | 1.45M |
| ChangeInPrepaidAssets | -845.50K | -101.87K | 39.91K | -48.95K |
| ChangeInReceivables | -2.10M | 0.00 | ||
| OtherNonCashItems | 215.86K | 1.41M | 2.23M | 1.21M |
| StockBasedCompensation | 2.47M | 4.66M | 6.38M | 6.19M |
| DepreciationAmortizationDepletion | 229.38K | 229.38K | 229.38K | 229.38K |
| DepreciationAndAmortization | 229.38K | 229.38K | 229.38K | 229.38K |
| AmortizationCashFlow | 229.38K | 229.38K | 229.38K | 229.38K |
| AmortizationOfIntangibles | 229.38K | 229.38K | 229.38K | 229.38K |
| OperatingGainsLosses | -3.77K | -2.04M | 1.44M | -3.29M |
| GainLossOnInvestmentSecurities | -3.77K | -2.04M | 1.44M | -3.29M |
| NetIncomeFromContinuingOperations | -17.54M | -32.12M | -50.26M | -26.08M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BIVI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|